Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
AssigneeSeattle Genetics, Inc.
InventorsEric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Claims25
1-23. (canceled)
A pharmaceutical composition comprising (i) about 1-25 mg/ml of an antibody-drug conjugate,
- having formula I:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- mAb is an anti-CD30 antibody;
- S is a sulfur atom of the antibody;
- and
- p is from about 3 to about 5,
- (ii) about 5-50 mM of a buffer selected from a citrate, phosphate, or histidine buffer or a combination thereof, (iii) about 3% to about 10% of a sugar selected from sucrose or trehalose or a combinations thereof, (iv) water, wherein the pH of the composition is from about 5.3 to about 7.
(canceled)
A method for treating a CD30-expressing hematologic cancer in a human subject, the method comprising administering to a subject in need thereof a dose of a pharmaceutical composition comprising (i) cAC10-MC-vc-PAB-MMAE, (ii) about 5-50 mM of a buffer selected from a citrate, phosphate, or histidine buffer or a combination thereof, (iii) about 3% to about 10% of a sugar selected from sucrose or trehalose or a combination thereof, and (iv) water, wherein the pH of the composition is from about 5.3 to about 7, wherein the administered dose of cAC10-MC-vc-PAB-MMAE is 1.8 mg/kg of the subject's body weight and the pharmaceutical composition is administered every three weeks.
Dependencies are inferred from the claim text.